# A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.

> **NCT00034619** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company**

## Conditions studied

- Colorectal Cancer

## Interventions

- **DRUG:** ALIMTA
- **DRUG:** Oxaliplatin

## Key facts

- **NCT ID:** NCT00034619
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2006-07-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00034619

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00034619, "A Phase 2 Trial of ALIMTA (LY231514, Pemetrexed) Plus Oxaliplatin Administered Every 21 Days for First-Line Treatment of Patients With Advanced Colorectal Cancer.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00034619. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*